GH Research PLC (GHRS) vs Syndax Pharmaceuticals, Inc. (SNDX)

A side-by-side comparison of GH Research PLC and Syndax Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — GHRS vs SNDX

growth of $100 · dividends reinvested · last 5y
GHRS +15.2% (+2.9%/yr)SNDX -1.8% (-0.4%/yr)GHRS compounded faster over this window
50100150Start $10020222023202420252026$115$98
GHRS SNDX

GHRS vs SNDX: by the numbers

  • •SNDX is the larger company ($1.54B vs $1.48B market cap).
  • •Both run net losses; GHRS's is the smaller (0.00% vs -87.60% net margin).

Metrics side by side

Valuation

MetricGHRSSNDX
P/S ratioN/A6.11
P/B ratio4.10101.94

Profitability

MetricGHRSSNDX
Gross margin0.00%97.47%
Operating margin0.00%-158.45%
Net margin0.00%-87.60%
ROE-17.32%-1462.12%
ROIC-19.87%-32.15%

Growth (annualized)

MetricGHRSSNDX
Revenue CAGR (5Y)N/A178.06%
Total return CAGR (5Y)0.52%-0.01%

Frequently asked

How have GHRS and SNDX total returns compared?
Over the past 5 years, GHRS delivered 0.52% and SNDX delivered -0.01% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.